RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/18992221http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/18992221http://www.w3.org/2000/01/rdf-schema#comment"Apolipoprotein CI (apoCI) has been suggested to influence HDL metabolism by activation of LCAT and inhibition of HL and CETP. However, the effect of apoCI on scavenger receptor BI (SR-BI)-mediated uptake of HDL-cholesteryl esters (CE), as well as the net effect of apoCI on HDL metabolism in vivo is unknown. Therefore, we evaluated the effect of apoCI on the SR-BI-mediated uptake of HDL-CE in vitro and determined the net effect of apoCI on HDL metabolism in mice. Enrichment of HDL with apoCI dose-dependently decreased the SR-BI-dependent association of [(3)H]CE-labeled HDL with primary murine hepatocytes, similar to the established SR-BI-inhibitors apoCIII and oxLDL. ApoCI deficiency in mice gene dose-dependently decreased HDL-cholesterol levels. Adenovirus-mediated expression of human apoCI in mice increased HDL levels at a low dose and increased the HDL particle size at higher doses. We conclude that apoCI is a novel inhibitor of SR-BI in vitro and increases HDL levels in vivo."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.org/dc/terms/identifier"doi:10.1016/j.bbrc.2008.10.147"xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"Jukema J.W."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"van Berkel T.J."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"Berbee J.F."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"Havekes L.M."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"Rensen P.C."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"Romijn J.A."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"van Dijk K.W."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"Out R."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"van der Hoogt C.C."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/author"de Haan W."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/date"2008"xsd:gYear
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/name"Biochem Biophys Res Commun"xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/pages"1294-1298"xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/title"Apolipoprotein CI inhibits scavenger receptor BI and increases plasma HDL levels in vivo."xsd:string
http://purl.uniprot.org/citations/18992221http://purl.uniprot.org/core/volume"377"xsd:string
http://purl.uniprot.org/citations/18992221http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/18992221
http://purl.uniprot.org/citations/18992221http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/18992221
http://purl.uniprot.org/uniprot/P02654#attribution-525826286EB76FEFE91443896B91235Dhttp://purl.uniprot.org/core/sourcehttp://purl.uniprot.org/citations/18992221
http://purl.uniprot.org/uniprot/#_A0A0R4J0I9-mappedCitation-18992221http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18992221
http://purl.uniprot.org/uniprot/#_D3Z5M3-mappedCitation-18992221http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18992221
http://purl.uniprot.org/uniprot/#_D3Z5U8-mappedCitation-18992221http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18992221
http://purl.uniprot.org/uniprot/#_E9Q643-mappedCitation-18992221http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/18992221